
FIGURE 1

A:



B:

Binding of -024 on CHO-CD38 cells.





FIGURE 2

A:


FITC fluorescence (arbitrary units)
1500
1250
1000
750
500
250
0
10^{-2}
10^{-1}
10^{0}
10^{1}
10^{2}
µg/ml
-003
-005
HuMab-KLH

B:



Mean FL1
400
300
200
100
0
10^{-3}
10^{-2}
10^{-1}
10^{0}
10^{1}
10^{2}
µg/ml
KLH
-024

FIGURE 3




10000
7500
5000
2500
0
mean fluorescence
10-3
10-2
10-1
100
101
102
antibody concentration (µg/ml)
-003
-005
-024
KLH

FIGURE 4

A:


100
75
50
25
0
lysis (%)
0.001
0.01
0.1
1
10
log conc µg/ml
-003
-005
rituximab
KLH

B:




ADCC on Daudi cells
Donor A
% lysis
log conc. ug/ml
KLH
-024
Donor B
% lysis
log conc. ug/ml
KLH
-024

FIGURE 5 (1/2)

A:



B:




FIGURE 6



70
60
50
40
30
20
10
0
% Lysis
0.0001
0.001
0.01
0.1
1
10
100
µg/ml
HuMab-KLH
-003
-005

FIGURE 7




FIGURE 8





FIGURE 9

A:


100
80
60
40
20
0
lysis (%)
0.01
0.1
1
10
100
conc. µg/ml
-003
-005
KLH

B:




90
80
70
60
50
40
30
20
10
0
% Lysis
0.001
0.01
0.1
1
10
100
1000
log conc. µg/ml
-024
KLH

FIGURE 10 (1/3)

A:



B:





FIGURE 10 (2/3)

C:



D:




FIGURE 10 (3/3)

E:




FIGURE 11




FIGURE 12

FIGURE 12A




FIGURE 12B




FIGURE 12C




FIGURE 12D




FIGURE 13

FIGURE 13A




FIGURE 13B



FIGURE 13C




FIGURE 13D






FIGURE 14


14A




14B



14C



14D



14E




FIGURE 15 (1/2)

FIGURE 15A




FIGURE 15B




FIGURE 15 (2/2)

FIGURE 15C




FIGURE 16

FIGURE 16A




FIGURE 16B




FIGURE 17 (1/2)

FIGURE 17A




FIGURE 17B




FIGURE 17 (2/2)

FIGURE 17C




FIGURE 17D




FIGURE 18



% dead cells
(Ann-V+ PI+)
55
50
45
40
35
30
25
20
15
10
5
0
--
rb-anti-hIgG
with or without cross-linking
HuMab-KLH
anti-CD20 mAb
-003
-005

FIGURE 19




FIGURE 20





FIGURE 21

A



B



C






FIGURE 22

A



B



C





FIGURE 23

A:


OD405
3
2
1
0
1
10
100
1000
10000
antibody (-003) concentration (ng/ml)
T237A
wt




OD405
3
2
1
0
1
10
100
1000
10000
antibody (-005) concentration (ng/ml)
T237A
wt

FIGURE 23

B:


3
2
1
0
OD405
1
10
100
1000
10000
antibody (-003) concentration (ng/ml)
Q272R
wt




3
2
1
0
OD405
1
10
100
1000
10000
antibody (-005) concentration (ng/ml)
Q272R
wt

FIGURE 23

C:


3
2
1
0
OD405
S274F
wt
1
10
100
1000
10000
antibody (-003) concentration (ng/ml)





3
2
1
0
OD405
S274F
wt
1
10
100
1000
10000
antibody (-005) concentration (ng/ml)

FIGURE 24

A:



B:



C:





FIGURE 25 (1/2)

A



B





FIGURE 25 (2/2)

C



D





FIGURE 26 (1/2)

A



B




FIGURE 26 (2/2)

C

